Efficacy and safety of a ceramide-based moisturizer for xerosis and chronic kidney disease associated pruritus in maintenance hemodialysis: a randomized controlled trial

Maulik Patel; Gaurang Patel; Girish Chaudhary; Akash Dholakia

doi:10.18203/issn.2455-4529.IntJResDermatol20263739

Authors

Maulik Patel Department of Nephrology, Shankus Hospital, Mehsana, Gujarat, India https://orcid.org/0009-0008-4941-3478
Gaurang Patel Department of Cardiology, Shankus Hospital, Mehsana, Gujarat, India
Girish Chaudhary Department of Pulmonary Medicine, Shankus Hospital, Mehsana, Gujarat, India
Akash Dholakia Department of Nephrology, Shankus Hospital, Mehsana, Gujarat, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20263739

Keywords:

Ceramide, Chronic kidney disease-associated pruritus, Hemodialysis, Moisturizer, Randomized controlled trial, Xerosis

Abstract

Background: Xerosis and chronic kidney disease-associated pruritus (CKD-aP) impair sleep and quality of life in patients receiving maintenance hemodialysis. Evidence for ceramide-based moisturizers in this population is limited.

Methods: This prospective, single-center, parallel-group randomized controlled trial assigned 130 adults receiving maintenance hemodialysis to a ceramide-based moisturizer applied twice daily for 8 weeks (n=65) or standard skin-care advice alone (n=65). Co-primary outcomes were changes from baseline to week 8 in Overall Dry Skin (ODS) and pruritus Visual Analog Scale (VAS) scores. Secondary outcomes included Dermatology Life Quality Index (DLQI), sleep disturbance, adherence, satisfaction, and adverse events.

Results: All participants completed follow-up. ODS scores decreased from 3.2±0.8 to 1.4±0.6 in the ceramide group and from 3.2±0.8 to 2.4±0.7 in controls (group-by-time interaction, p<0.001). VAS scores decreased from 7.1±1.3 to 2.3±1.2 and from 7.0±1.4 to 5.1±1.5, respectively (p<0.001). DLQI scores decreased from 12.1±3.4 to 4.8±2.1 and from 11.8±3.2 to 8.9±2.9, respectively (p<0.001). Sleep disturbance and satisfaction also favored the ceramide group. No serious treatment-related adverse events occurred.

Conclusions: A ceramide-based moisturizer improved xerosis, CKD-aP, dermatology-related quality of life, and sleep disturbance compared with standard skin-care advice alone. Active-comparator trials are needed to determine whether the benefit is specific to ceramides or reflects moisturization generally.

References

Mathur VS, Lindberg J, Germain M, Block G, Tumlin J, Smith M, et al. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1410-9.

Pisoni RL, Wikström B, Elder SJ, Akizawa T, Asano Y, Keen ML, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2006;21:3495-505.

Rayner HC, Larkina M, Wang M, Graham-Brown MPM, van der Veer SN, Ecder T, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 2017;12:2000-7.

Kimata N, Fuller DS, Saito A, Akizawa T, Fukuhara S, Pisoni RL, et al. Pruritus in hemodialysis patients: results from the Japanese Dialysis Outcomes and Practice Patterns Study (JDOPPS). Hemodial Int 2014;18:657-67.

Zucker I, Yosipovitch G, David M, Gafter U, Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003;49:842-6. doi:

Ozen N, Cinar FI, Askin D, Mut D. Uremic pruritus and associated factors in hemodialysis patients: a multi-center study. Kidney Res Clin Pract 2018;37:138-47.

Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006;69:1626-32.

Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006;21:749-55.

Mettang T, Kremer AE. Uremic pruritus. Kidney Int 2015;87:685-91.

Yamamoto S, Tanaka T, Omori K, Ei I, Kikuchi K, Konagai A, et al. Pruritus and protein-bound uremic toxins in patients undergoing hemodialysis: a cross-sectional study. Clin Kidney J 2024;17:sfae007.

Ko MJ, Peng YS, Wu HY. Uremic pruritus: pathophysiology, clinical presentation, and treatments. Kidney Res Clin Pract 2023;42:39-52.

Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006;7:535-47.

Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003;361:690-4.

Chang PC, Liao IC. Hydration, barrier of skin and uremic pruritus in patients undergoing hemodialysis: a pilot investigation. Nephrol Ther 2022;18:498-505.

Krismi A, Danarti R, Setiabudi IIDPP, Wirohadidjojo YW. Chronic kidney disease-associated pruritus in patients undergoing hemodialysis: xerosis and topical therapy. Hemodial Int 2023;27:91-104.

Madison KC. Barrier function of the skin: "La raison d'être" of the epidermis. J Invest Dermatol 2003;121:231-41.

Feingold KR. The outer frontier: the importance of lipid metabolism in the skin. J Lipid Res 2009;50 Suppl:S417-22.

van Smeden J, Janssens M, Gooris GS, Bouwstra JA. The important role of stratum corneum lipids for the cutaneous barrier function. Biochim Biophys Acta 2014;1841:295-313.

Draelos ZD. The science behind skin care: moisturizers. J Cosmet Dermatol 2018;17:138-44.

Man MQ, Feingold KR, Thornfeldt CR, Elias PM. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996;106:1096-101.

Man MQ, Feingold KR, Elias PM. Exogenous lipids influence permeability barrier recovery in acetone-treated murine skin. Arch Dermatol 1993;129:728-38.

Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, et al. Ceramide-dominant barrier-repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208.

Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014;134:818-23.

Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005;13(2):97-103.

Okada K, Matsumoto K. Effect of skin care with an emollient containing a high water content on mild uremic pruritus. Ther Apher Dial 2004;8:419-22.

Boaz M, Shtendik L, Oron M, Portugal-Cohen M, Kohen R, Biro A, et al. A randomized controlled clinical trial comparing the efficacy of Dead Sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT). Nephron Clin Pract 2009;113:c169-76.

Yoshida Y, Hirama A, Hashimoto K, Sato T, Yokota N, Saeki H, et al. Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: a multicenter, open-label, randomized verification study. J Dermatol 2021;48:1327-35.

Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007;87:291-4.

Weisshaar E, Müller S, Szepietowski JC, Dalgard F, Garcovich S, Kupfer J, et al. European S2k guideline on chronic pruritus: in cooperation with the European Dermatology Forum. Acta Derm Venereol 2025;105:adv44220.

Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-9.

Foroutan N, Etminan A, Nikvarz N, Shojai Shahrokh Abadi M. Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single-blind clinical trial. Hemodial Int 2017;21:63-71.

Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F; KALM-1 Trial Investigators. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 2020;382:222-32.

Topf J, Wooldridge T, McCafferty K, Schömig M, Csiky B, Zwiech R, et al. Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies. Kidney Med 2022;4:100512.

Ko MJ, Yang JY, Wu HY, Hu FC, Chen SI, Tsai PJ, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol 2011;165:633-9.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.

Simonsen E, Komenda P, Lerner B, Askin N, Bohm C, Shaw J, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis 2017;70:638-55.

Verduzco HA, Shirazian S. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep 2020;5:1387-402.